NUVESSA 1.3% and XACIATO 2% are prescription vaginal gels with single-administration labeling for bacterial vaginosis. That makes them a useful gel-to-gel comparison, but it does not make them the same medicine. Nuvessa contains metronidazole, while Xaciato contains clindamycin phosphate. The ingredient difference brings different labeled cautions, package designs and possible reasons for a clinician to choose one rather than the other.
Unlike Clindesse, which is a clindamycin vaginal cream, Xaciato is a gel. Its label describes a tube and a user-filled single-use vaginal applicator, while Nuvessa uses a single-dose prefilled applicator. The details can matter during counseling and when a pharmacy verifies a package. They do not prove an advantage in effectiveness or justify exchanging one product without a new prescribing decision.
The comparison focuses on the two named brands. Readers needing the separate gel-versus-cream choice can use Nuvessa versus Clindesse. For this pair, refer to Nuvessa’s label and product identity and Xaciato prescription access before discussing legitimate dispensing options.
This comparison starts with the product, route and indication rather than a promise that one medicine is faster, stronger or cheaper. The differences in the matrix help a patient identify exactly what a clinician has prescribed for Nuvessa vs Xaciato. They are not a self-treatment chart, and the actual product label should control administration.
Both packages are single-dose vaginal gels, yet the dispensing equipment is not alike. Nuvessa has a prefilled applicator; Xaciato includes a user-filled disposable applicator and its label identifies polyurethane-condom limitations. Those differences are practical reasons to read the exact supplied label and ask questions rather than rely on an abbreviated pharmacy description.
| Comparison point | NUVESSA | XACIATO |
|---|---|---|
| Feature | NUVESSA | XACIATO |
| Ingredient | Metronidazole | Clindamycin phosphate |
| Gel strength | 1.3% | 2% |
| Indication | BV | BV |
| Labeled course | Single vaginal dose | Single vaginal dose |
| Applicator | Prefilled | User-filled disposable applicator from tube |
| Important barrier caution | Follow Nuvessa labeling | Polyurethane-condom warning during and 7 days after treatment |
| Other vaginal-activity counseling | Follow the current NUVESSA patient instructions | Avoid vaginal sex, tampons and douches during treatment and for 3 days afterward |
| Same drug or generic? | No | No |
The shared vaginal gel form does not remove the distinction between the molecules. Metronidazole is a nitroimidazole antimicrobial; clindamycin is a lincosamide antibiotic. Their adverse effects, contraindications and application instructions should be reviewed separately. A clinician selecting a drug for BV may consider previous reactions, other health conditions and patient needs.
A product switch between Nuvessa and Xaciato changes the active ingredient. It is not the same as exchanging an approved 1.3% metronidazole generic for Nuvessa where applicable regulations and the prescription allow it.
Nuvessa comes as a single-dose prefilled vaginal applicator. Xaciato’s labeling describes an 8 g tube with a user-filled disposable applicator that delivers a 5 g gel dose. These are product-specific devices; the extra material in a tube does not authorize more administrations.
A patient should be shown how the actual package is used, particularly if dexterity, vision or comfort makes a user-filled applicator challenging. Never refill or reuse disposable equipment unless the product’s instructions explicitly direct otherwise; these are one-time products.
The Xaciato label warns that polyurethane condoms should not be used during treatment and for seven days afterward because the gel can weaken them. The label distinguishes polyurethane from latex or polyisoprene products. This precise detail differs from Clindesse’s mineral-oil-related latex/rubber warning and should not be merged into one generic clindamycin rule.
The XACIATO instructions also direct patients to avoid vaginal intercourse and other vaginal products, including tampons and douches, during treatment and for three days afterward. This three-day restriction is separate from the seven-day polyurethane-condom caution. For the latter period, the label identifies latex or polyisoprene condoms as alternatives. Confirm contraception and STI-prevention needs with a clinician or pharmacist; NUVESSA has its own patient instructions.
Xaciato labeling contains C. difficile-associated diarrhea precautions, and vaginal yeast infection may occur during or after antibiotic exposure. Nuvessa also has product-specific adverse effects and warnings. A vaginal route does not eliminate all systemic or microbiologic consequences.
Patients with a history of colitis, relevant allergies or previous severe antibiotic reactions should bring that information to the prescriber. Persistent discharge or itching after treatment could reflect several causes and should not be treated by adding an antifungal or repeating antibiotics automatically.
FDA approved a generic metronidazole vaginal gel 1.3% referencing Nuvessa in 2024. This approval has no implication that a generic Xaciato exists, is medically appropriate or is stocked by any specific pharmacy. Drug application approval and real pharmacy inventory are separate concepts.
When an insurer prefers one gel or refuses a claim, the pharmacy should identify the exact product and ask the prescriber to assess any new active ingredient. Comparing package prices does not authorize substituting clindamycin for metronidazole.
Ask the dispensing pharmacist to confirm the drug, strength, vaginal route, applicator design and labeled one-dose nature of the prescription. This is especially useful when a catalog entry says only “vaginal antibiotic gel.”
Questions about aftercare and condom compatibility should be answered using the specific dispensed label. If the product seems different from the original prescription, request clarification before use rather than relying on brand similarities or the shared gel texture.
A patient receiving Xaciato will encounter a tube and user-filled applicator, while Nuvessa’s labeled product is prefilled. The dispensing pharmacist should make sure the patient understands the single-use nature of the package and can follow the correct instructions. Confusing a tube’s total fill amount with the intended applicator amount would be an avoidable medication error. The vaginal prescription guide addresses why route, package and quantity must be clear.
The Xaciato polyurethane-condom warning may be unfamiliar to someone who has previously used a clindamycin cream with mineral oil. In particular, the warning is not identical to the one associated with Clindesse, and it should not be reduced to a generalized instruction that all condoms are incompatible with all vaginal antibiotics.
The named gels also belong to different purchasing workflows. Metronidazole vaginal gel purchasing should remain focused on prescriptions for that drug, while Xaciato access addresses the branded clindamycin product. A pharmacy stock notice for one cannot establish that the other is a reasonable prescription substitute.
Begin with the specific question answered on this page: Side-by-side gel-to-gel single-dose comparison with distinct ingredients, applicators and safety notes. Do not use a comparison page to diagnose an infection or choose an antibiotic without a licensed clinician. Identify the medical purpose of the current prescription and check that the intended medicine, dosage form and route are clear enough for the dispensing pharmacist to verify.
A prescription for Xaciato should identify clindamycin vaginal gel and the supplied user-filled applicator, whereas Nuvessa is the prefilled metronidazole vaginal gel. The pharmacy should explain the polyurethane-condom restriction for Xaciato when relevant. A label discrepancy, missing applicator or unexpectedly different brand requires clarification before use.
Yes, but they contain different antibiotics and use different applicator designs.
No. It contains clindamycin phosphate.
Yes. Its label describes a one-time vaginal dose using a filled applicator.
Yes. The XACIATO label advises against polyurethane condoms during treatment and for seven days afterward because they may be weakened. Latex or polyisoprene condoms are identified as options. This warning is separate from the three-day restriction on vaginal intercourse and other vaginal products.
No. XACIATO warns specifically about polyurethane condoms for seven days after treatment, whereas mineral-oil-containing CLINDESSE warns about latex or rubber condoms and diaphragms during and for five days after treatment. Refer to the exact dispensed product label.
The labeled Nuvessa single-dose presentation uses a prefilled applicator.
An equivalent 1.3% generic has FDA approval, but local supply is not guaranteed.
No. Switching active ingredients requires clinician assessment and an appropriate prescription.
Neither is an antifungal treatment for yeast infection.
Compare the exact drug, strength, applicator type and instructions with the written prescription and ask the pharmacist to resolve differences.